ResearcherOmaha VA Medical CenterActive in the last 2 years
Mark A. Carlson
Matched on ORCID iD 0000-0002-8113-9199; OpenAlex author ID A5103191977; NIH RePORTER profile ID 1865926. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 1)
- Trials
- 0
- Grants
- 1
- Labs led
- 1
- Collaborators
- 12
2018: 1 paper · 2019: 1 paper · 2020: 1 grant · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper
Papers 5
- MUC16 Retention after Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16203439↗
- Mucins as contrast agent targets for fluorescence-guided surgery of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2023.216150↗
- Preclinical Evaluation of a Humanized, Near-Infrared Fluorescent Antibody for Fluorescence-Guided Surgery of MUC16-Expressing Pancreatic Cancer. Co-author DOI 10.1021/acs.molpharmaceut.2c00203↗
- Porcine Models of Pancreatic Cancer. First author DOI 10.3389/fonc.2019.00144↗
- Generation of tumorigenic porcine pancreatic ductal epithelial cells: toward a large animal model of pancreatic cancer Last author DOI 10.1101/267112↗
Grants 1
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kathryn M. Muilenburg · 3 shared papers, 2022–2024 · strength 0.55
- Paper MUC16 Retention after Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers16203439↗
- Paper Mucins as contrast agent targets for fluorescence-guided surgery of pancreatic cancer. DOI 10.1016/j.canlet.2023.216150↗
- Paper Preclinical Evaluation of a Humanized, Near-Infrared Fluorescent Antibody for Fluorescence-Guided Surgery of MUC16-Expr… DOI 10.1021/acs.molpharmaceut.2c00203↗
- Aaron M. Mohs · 3 shared papers, 2022–2024 · strength 0.55
- Paper MUC16 Retention after Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers16203439↗
- Paper Mucins as contrast agent targets for fluorescence-guided surgery of pancreatic cancer. DOI 10.1016/j.canlet.2023.216150↗
- Paper Preclinical Evaluation of a Humanized, Near-Infrared Fluorescent Antibody for Fluorescence-Guided Surgery of MUC16-Expr… DOI 10.1021/acs.molpharmaceut.2c00203↗
- Michael Anthony Hollingsworth · 3 shared papers, 2018–2023 · strength 0.43
- Paper Mucins as contrast agent targets for fluorescence-guided surgery of pancreatic cancer. DOI 10.1016/j.canlet.2023.216150↗
- Paper Preclinical Evaluation of a Humanized, Near-Infrared Fluorescent Antibody for Fluorescence-Guided Surgery of MUC16-Expr… DOI 10.1021/acs.molpharmaceut.2c00203↗
- Paper Generation of tumorigenic porcine pancreatic ductal epithelial cells: toward a large animal model of pancreatic cancer DOI 10.1101/267112↗
- Geoffrey A. Talmon · 2 shared papers, 2022–2024 · strength 0.37
- Madeline T. Olson · 2 shared papers, 2022–2024 · strength 0.37
- Katie L. Bailey · 1 shared paper, 2019 · strength 0.20
- Michael Bouvet · 1 shared paper, 2023 · strength 0.18
- Surinder K. Batra · 1 shared paper, 2023 · strength 0.18
- Prakash Radhakrishnan · 1 shared paper, 2023 · strength 0.18
- Eric N. Aguilar · 1 shared paper, 2022 · strength 0.15
- Neeley A. Remmers · 1 shared paper, 2018 · strength 0.09
- Jesse L. Cox · 1 shared paper, 2018 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.